Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (000766.SZ) has released its annual report for 2025. During the reporting period, the company achieved operating revenue of 1.17 billion yuan, representing a decrease of 11.54% year-on-year. Net profit attributable to shareholders of the listed company was 34.2865 million yuan, a decline of 39.25% compared to the previous year. Net profit attributable to shareholders of the listed company, after deducting non-recurring gains and losses, was 27.2199 million yuan, down 43.26% year-on-year. Basic earnings per share were 0.04 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments